Lymphoma

Natural Killer Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 13:33:41 +0000

Summary

Natural Killer Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Natural Killer Cell Lymphomas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Natural Killer Cell Lymphomas, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’...

$2,000.00

Primary Mediastinal B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 13:33:41 +0000

Summary

Primary Mediastinal B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global...

$2,000.00

Marginal Zone B-cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 13:33:41 +0000

Summary

Marginal Zone B-cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’...

$2,500.00

Hemophagocytic Lymphohistiocytosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Hemophagocytic Lymphohistiocytosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Hemophagocytic Lymphohistiocytosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hemophagocytic Lymphohistiocytosis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Ma...

$2,000.00

Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Lymphoblastic Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lymphoblastic Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databas...

$2,000.00

Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Splenic Marginal Zone B-Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Splenic Marginal Zone B-Cell Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from ...

$2,000.00

Primary CNS Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Primary CNS Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Primary CNS Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary CNS Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, co...

$2,000.00

Cutaneous T-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 15:59:09 +0000

Summary

Cutaneous T-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietar...

$2,000.00

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
<...

$2,500.00

Burkitt Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 13:47:50 +0000

Summary

Burkitt Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Burkitt Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/univer...

$2,000.00

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 03 Jun 2022 13:17:15 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action ...

$2,500.00

Global Cutaneous T-cell Lymphoma Market-by type, by treatment, Epidemiology insight & Competitive Analysis - Global forecast to 2030

Wed, 11 May 2022 11:50:02 +0000

The global cutaneous T-cell Lymphoma market is expected to grow at a CAGR of 8.56% from 2020 to reach USD 3531.5 million by 2030. The growth is primarily attributed to rapidly growing geriatric population, rising prevalence of lymphoma cancer, advancements in treatments, increasing research & development for novel treatment options, government funding & initiatives and growing demand for better treatments available to cancer patients. However, lack of expertise, high cost of treatment, potential side effects associated with chemotherapy and requirement of tailored treatments due to rarity of cutaneous T-cell Lymphoma can hinder the growth of this market. By Type: Mycosis Fungoides segment to register highest CAGR Cutaneous T-cell Lymphoma market is segmented into Mycosis Fungoides, Sezary Syndrome and other types. In this segmentation, Mycosis Fungoides segment is expected to grow at the highest CAGR. The high growth of this segment can be attributed to higher occurrence as compared to other types, difficult diagnosis and higher susceptibility in geriatric patients. By Treatment:...

$4,250.00

Global B-Cell Non-Hodgkin’s Lymphoma (NHL) Market Research Report 2021-2025

Wed, 08 Sep 2021 15:45:00 +0000

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. B-Cell Non-Hodgkin’s Lymphoma (NHL) Report by Material, Application, and Geography – Global Forecast to 2025 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). In this report, the global B-Cell Non-Hodgkin’s Lymphoma (NHL) market is valued at USD XX million in 2021 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2021 to 2025. The report firstly introduced the B-Cell Non-Hodgkin’s Lymphoma (NHL) basics: definitions, classifications, applica...

$3,200.00

Follicular Lymphoma – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “Follicular Lymphoma – Pipeline Insight, 2020,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Follicular Lymphoma Understanding Follicular Lymphoma: Overview Lymphoma is a type of blood cancer that develops when white blood cells called lymphocytes grow out of control. Lymphocytes are part of your immune system. They travel around your body in your lymphatic system, and blood, helping you fight infections. There are two types of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). Lymphomas can be grouped as Hodgkin lymphomas or non-Hodgkin lymphomas, depending on the types of cell they contain. Follicular lymphoma is a common type of slow-growing (low-grade) non-Hodgki...

$2,500.00

Diffuse Large B-cell Lymphoma (DLBCL) – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “Diffuse Large B-cell Lymphoma (DLBCL) – Pipeline Insight, 2020,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diffuse Large B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Diffuse Large B-cell Lymphoma Understanding Diffuse Large B-cell Lymphoma (DLBCL): Overview Lymphoma is a type of blood cancer that develops when white blood cells called lymphocytes grow out of control. Lymphocytes are part of your immune system. They travel around your body in your lymphatic system, helping you fight infections. There are two types of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). There are lots of different types of lymphoma. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). It is a ...

$2,500.00

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Market Insight, Epidemiology and Market Forecast - 2030

Mon, 15 Jun 2020 15:08:36 +0000

DelveInsight's "Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma, historical and forecasted epidemiology as well as the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Mucosa-associated Lymphoid Tissue (MALT) Lymphoma market report provides current treatment practices, emerging drugs, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma market share of the individual therapies, current and forecasted Mucosa-associated Lymphoid Tissue (MALT) Lymphoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Mucosa-associated Lymphoid Tissue (MALT) Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Geography Covered • The United States ...

$6,950.00

Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H2, 2019

Mon, 24 Feb 2020 15:56:48 +0000

Summary

GlobalData's clinical trial report, “Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Peripheral T-Cell Lymphomas (PTCL) clinical trials scenario. This report provides top line data relating to the clinical trials on Peripheral T-Cell Lymphomas (PTCL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and...

$2,500.00

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019

Wed, 11 Dec 2019 11:38:48 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Pipeline Review, H2 2019, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA...

$2,000.00

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2019

Wed, 11 Dec 2019 11:38:48 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2019, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with ...

$2,000.00

Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027

Fri, 21 Dec 2018 11:52:10 +0000

Summary

Chronic lymphocytic leukemia (CLL) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C91.1), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and diagnosed prevalent cases forecast for the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized. In cases of data scarcity, appropriate proxies were used to fill the data gaps.

The diagnosed incident cases of CLL in the 7MM will increase from 41,974 cases in 2017 to 50,474 cases in 2027, at an Annual Growth Rate (AGR) of 2.03% over the forecast period. For the majority of the forecast period, the US will have the highest number of diagnosed in...

$3,995.00

AIDS - Related Lymphoma Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “AIDS - Related Lymphoma Global Clinical Trials Review, H2, 2018" provides an overview of AIDS - Related Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS - Related Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strate...

$2,500.00

AIDS - Related Primary CNS Lymphoma Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “AIDS - Related Primary CNS Lymphoma Global Clinical Trials Review, H2, 2018" provides an overview of AIDS - Related Primary CNS Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS - Related Primary CNS Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps t...

$2,500.00

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Global Therapeutic Clinical Trials Review, H2, 2018

Thu, 06 Dec 2018 11:59:08 +0000

Summary

GlobalData's clinical trial report, “Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Global Clinical Trials Review, H2, 2018" provides an overview of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. $2,500.00

T-Cell Lymphomas Global Clinical Trials Review, H2, 2018

Wed, 17 Oct 2018 16:06:20 +0000

Summary

GlobalData's clinical trial report, “T-Cell Lymphomas Global Clinical Trials Review, H2, 2018" provides an overview of T-Cell Lymphomas clinical trials scenario. This report provides top line data relating to the clinical trials on T-Cell Lymphomas. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competit...

$2,500.00

Lymphoma Treatment Drugs Markets in China

Wed, 09 May 2018 11:25:43 +0000

China's demand for Lymphoma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews a...

$4,000.00